University of California, Berkeley has licensed breakthrough technology enabling the fermentation-based production of high-purity cannabinoids. The intellectual property was developed by Jay Keasling, PhD. Demetrix understands that cannabinoids are the active compounds found in the cannabis plant and have demonstrated therapeutic benefits representing a potential multi-billion dollar industry. With over 113 unique cannabinoids (THC and CBD being the most common), Demetrix seeks to integrate the UC Berkeley-originated technology into its proprietary platform. It seeks to not only produce new cannabinoid-based treatments but do so faster and cheaper if they are able to leverage and harness the power of Keasling’s work—which was highlighted in the February 27, 2019 issue of Nature.